U.S. Aesthetic Medicine Market (2026 - 2033)

U.S. Aesthetic Medicine Market Summary

The U.S. aesthetic medicine market size was valued at USD 18.8 billion in 2025 and is projected to grow from USD 19.9 billion in 2026 to USD 32.0 billion by 2033, at a CAGR of 7.0% from 2026 to 2033. The market is primarily driven by the increasing preference for minimally invasive cosmetic procedures that offer shorter recovery times, lower procedural risks, and natural-looking outcomes. Growing consumer awareness, increasing disposable income, and the rising acceptance of aesthetic treatments among younger adults and men are contributing to higher demand for injectables, skin rejuvenation procedures, and body contouring treatments. 

Healthcare providers are also expanding their portfolios with advanced injectable products and energy-based technologies to address the growing patient base. For instance, in July 2024, Merz Aesthetics received U.S. FDA approval for XEOMIN to temporarily improve the appearance of moderate-to-severe platysma bands in adults, expanding its facial aesthetics portfolio in the U.S.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Market Dynamics

Driver: Rising Demand for Minimally Invasive and Non-Invasive Aesthetic Procedures

The increasing preference for minimally invasive and non-invasive aesthetic procedures is a major driver of the market. Consumers are seeking effective aesthetic enhancements that deliver visible results without the risks, recovery periods, and costs associated with traditional surgical interventions. For instance, according to the American Society of Plastic Surgeons (ASPS), the following aesthetic procedures were performed in the U.S. in 2024:

• Total Aesthetic Procedures: 6,165,173
• Total Surgical Procedures: ~2.10 million
• Total Non-surgical Procedures: ~4.06 million

 

Surgical Procedures	Number of Procedures (2024)	Non-Surgical Procedures	Number of Procedures (2024)
Liposuction	342,751	Botulinum Toxin	1,794,384
Breast Augmentation	227,470	Hyaluronic Acid Fillers	1,229,041
Scar Revision	190,854	Non-surgical Skin Tightening	356,072
Eyelid Surgery (Blepharoplasty)	114,030	Chemical Peel	170,203
Rhinoplasty	39,978	Hair Removal	157,756

Get access to detailed company insights of key market participants. To know more request a free sample copy

Source: ISAPS Global Survey 2024, Grand View Research Analysis

Advanced laser systems, radiofrequency devices, ultrasound-assisted technologies, and plasma-based treatments are increasingly used for skin tightening, fat reduction, scar revision, and anti-aging applications. For instance, in October 2025, Cynosure Lutronic launched eCO2 3D, a fractional CO2 laser for skin resurfacing. The system offers interchangeable 120μm, 300μm, and 500μm tips in a 40-watt platform, enabling customizable treatment depth and density for wrinkles, scars, textural irregularities, and other dermatologic indications.

To learn more about this report, Download Free Sample Report

Growing awareness of preventive aesthetics and increasing demand among younger consumers are further accelerating adoption. Individuals in their twenties and thirties are increasingly utilizing minimally invasive treatments to maintain youthful appearances and delay visible signs of aging. Social media exposure, virtual consultations, and enhanced accessibility through specialized aesthetic clinics and medical spas have expanded market reach and consumer engagement. In addition, repeat treatment requirements for injectables and other non-surgical procedures create recurring demand, supporting sustained revenue generation for providers. This shift toward less invasive aesthetic solutions continues to drive growth in the aesthetic medicine market in the U.S.

Restraint: High Cost of Aesthetic Procedures and Limited Insurance Coverage

The growth of the market is restrained by the high cost of aesthetic procedures and the lack of insurance reimbursement for elective cosmetic treatments. Most aesthetic procedures, including botulinum toxin injections, dermal fillers, laser skin resurfacing, body contouring, and cosmetic surgeries, are performed for aesthetic enhancement rather than medical necessity. Consequently, these procedures are generally not covered by private health insurance or public healthcare programs such as Medicare and Medicaid, requiring patients to bear the full cost out of pocket. The cumulative financial burden becomes more significant for patients undergoing multiple procedures or maintenance treatments, such as botulinum toxin injections and dermal fillers, which require repeat sessions every few months to maintain clinical results.

 

Procedure (U.S., 2024)	Average Surgeon Fee Range
Facelift	USD 12,000-19,000
Rhinoplasty	USD 7,500-12,500
Abdominoplasty (Tummy Tuck)	USD 8,000-13,500
Liposuction	USD 4,300-7,500
Breast Augmentation	USD 4,575-8,000
Neck Lift	USD 7,500-13,000

Source: 2024 ASPS Report, Grand View Research Analysis

Around 30.9 million aesthetic procedures were performed in the U.S. in 2024; however, most cosmetic procedures are elective and are not covered by public or private health insurance, making affordability a major barrier to treatment adoption. Patients must bear the entire cost of procedures, including surgeon fees, anesthesia, facility charges, and follow-up care. Furthermore, the recurring nature of minimally invasive treatments, such as botulinum toxin injections and dermal fillers, increases long-term treatment costs, thereby limiting adoption among cost-conscious consumers despite growing demand for services.

Opportunity: Increasing Adoption of AI-Powered Treatment Planning and Facial Analysis

AI-powered facial analysis and skin assessment platforms are enabling practitioners to evaluate facial symmetry, skin quality, anatomical proportions, and aging patterns with greater accuracy, facilitating personalized treatment planning and improving clinical decision-making. These technologies support data-driven consultations, helping providers recommend customized surgical and non-surgical procedures based on individual patient characteristics and aesthetic goals. As U.S. aesthetic clinics increasingly adopt digital technologies to enhance treatment precision and patient experience, AI-based consultation platforms are expected to become a key competitive differentiator.

AI-driven simulation and visualization tools are also transforming patient engagement by allowing individuals to preview potential treatment outcomes before undergoing aesthetic procedures. Three-dimensional imaging and virtual simulation technologies improve communication between practitioners and patients, align treatment expectations with achievable results, and support informed decision-making, thereby increasing patient confidence and treatment acceptance rates. For instance, in April 2026, Perfect Corp. partnered with Keensight to integrate AI-powered skin analysis into the Lummitry 3D consultation platform. The solution utilizes mobile facial imaging to generate accurate 3D facial models, improve consultation quality, reduce decision-making time, and enhance conversion rates for aesthetic practices.

"Perfect Corp.’s AI technology offers global-level accuracy and stability, making it the ideal choice for enhancing our 3D-based consulting experience," said Hyunsoo Cho and Joseph Kim, Co-Founders of Keensight

Growing investments in AI-enabled patient engagement solutions are further creating opportunities for aesthetic providers across the U.S. AI-powered communication platforms help automate appointment scheduling, patient follow-ups, treatment education, and lead management, improving operational efficiency while enhancing patient satisfaction. For instance, in May 2026, AI Med Consult partnered with MedShark Digital to combine AI-driven patient engagement with digital marketing capabilities, enabling aesthetic practices to improve patient acquisition and streamline front-office workflows.

"Patients are increasingly seeking treatments that work at a deeper biological level to improve skin health, not just appearance," said Dr. Dean Vistnes, Co-founder and Medical Director at SkinSpirit

Challenge: Growing Availability of Counterfeit Injectables and Unlicensed Providers

The growth of the market is hindered by the rising prevalence of counterfeit aesthetic products and treatments performed by unlicensed providers. The rising popularity of botulinum toxin injections and dermal fillers has led to the emergence of unauthorized suppliers offering counterfeit or unapproved products at significantly lower prices. These products may contain unknown ingredients, be improperly stored, or be compromised in sterility, increasing the risk of severe adverse events such as infection, tissue necrosis, vision impairment, and hospitalization. Concerns about patient safety undermine consumer confidence and spur stricter regulatory oversight, creating challenges for legitimate manufacturers and healthcare providers.

For instance, in April 2024, the U.S. Food and Drug Administration (FDA) warned healthcare professionals and consumers that counterfeit Botox had been identified in multiple U.S. states and was associated with adverse events, including hospitalizations. The FDA advised providers to purchase botulinum toxin products only through authorized distributors and reminded consumers that injectable cosmetic products should only be administered by licensed healthcare professionals.

Case Study: Personalized Laser-Based Rosacea Treatment and Skin Rejuvenation

Patient Profile:

A female patient in her 40s presented with persistent facial erythema, flushing, inflammatory papules, and telangiectasia associated with rosacea. In addition to rosacea symptoms, the patient sought treatment for age-related skin concerns, including uneven skin texture and early signs of facial aging.

Clinical Objective:

The clinical objective was to reduce facial redness and inflammation associated with rosacea, improve overall skin quality, and achieve facial rejuvenation through a personalized, minimally invasive treatment approach.

Procedure Overview:

The patient underwent a customized treatment protocol combining prescription skincare with energy-based aesthetic procedures, including vascular laser therapy to reduce diffuse erythema and visible blood vessels. Follow-up consultations were conducted to evaluate treatment response and adjust the treatment plan based on clinical improvement.

Results & Diagnosis:

Following the treatment course, clinical assessment demonstrated a visible reduction in facial erythema and telangiectasia, along with improvements in skin texture, tone, and overall facial appearance. The patient tolerated the treatment well, with no major complications reported, highlighting the effectiveness of individualized, minimally invasive aesthetic treatments for managing rosacea while simultaneously addressing cosmetic skin concerns.

Market Concentration & Characteristics

The chart below illustrates the relationship among industry concentration, industry characteristics, and industry participants in the market. The market is highly fragmented, with numerous medical spas, dermatology clinics, and plastic surgery practices offering diverse services. It is characterized by a high degree of innovation, moderate merger and acquisition activity, strong regulatory oversight, and continuous expansion driven by increasing demand for minimally invasive aesthetic procedures and advanced treatment technologies.

To learn more about this report, Download Free Sample Report

The industry is experiencing a high degree of innovation, driven by continuous advancements in minimally invasive procedures, regenerative aesthetics, artificial intelligence, and energy-based treatment technologies. Service providers are increasingly adopting AI-powered skin analysis, personalized treatment planning, and next-generation laser and radiofrequency platforms to improve patient outcomes. For instance, in July 2026, SkinSpirit expanded its regenerative aesthetics portfolio by launching a PDRN (Salmon DNA) Microneedling Catalyst Serum Treatment to address the growing demand for advanced skin rejuvenation therapies.

Source: 2025 AAD: New Technologies for Face and Body Treatments, Modern Aesthetics

The level of mergers and acquisitions is moderate to high, supported by rising private equity investment and consolidation among medical spa and aesthetic clinic networks. Leading providers continue to expand their geographic footprint and service offerings through acquisitions and strategic partnerships, strengthening their presence in the highly competitive U.S. market.In September 2025, Spa Medicca completed the strategic acquisition of Skin Science Aesthetics, with Viper Partners serving as the exclusive financial advisor. The transaction expanded Spa Medicca's presence in Florida, strengthened its aesthetic service portfolio, and supported its long-term regional growth strategy through an established clinical platform.

The industry operates under a high level of regulatory oversight, with aesthetic medical devices, dermal fillers, laser systems, and botulinum toxin products regulated by the U.S. Food and Drug Administration. In addition, physicians and aesthetic practitioners must comply with state-specific licensing requirements and clinical practice standards to ensure patient safety and treatment quality.

The U.S. aesthetic medicine market continues to expand, driven by the introduction of advanced treatment technologies and the rapid growth of medical spas and specialty aesthetic clinics. The expansion of multi-location medical spa chains, coupled with rising private equity investments and growing adoption of AI-enabled consultation platforms, is further enhancing access to aesthetic services across the country. These developments are enabling providers to improve treatment outcomes, enhance patient experience, and strengthen their competitive position, supporting sustained market growth.

Analyst Perspective

The U.S. aesthetic medicine market is driven by growing demand for minimally invasive and non-invasive cosmetic procedures, driven by rising aesthetic awareness, increasing disposable income, and the growing emphasis on appearance across all age groups. The increasing adoption of injectable treatments, laser-based procedures, body contouring, skin rejuvenation, and facial aesthetic solutions, coupled with the expanding aging population seeking anti-aging treatments, is supporting market growth. Furthermore, continuous advancements in energy-based devices, AI-enabled aesthetic technologies, personalized treatment approaches, and shorter recovery procedures are improving treatment outcomes, enhancing patient satisfaction, and driving broader adoption of aesthetic medicine services across dermatology clinics, medical spas, hospitals, and specialty aesthetic centers.

Procedure Insights

The non-invasive segment held a significant share of 53.6% in 2025. The segment is growing due to ongoing technological advancements in surgical planning, implant technologies, and body-contouring systems, enabling surgeons to improve procedural precision, enhance patient safety, and deliver more predictable aesthetic outcomes. The integration of digital planning tools, three-dimensional visualization, and advanced surgical devices is streamlining preoperative planning and supporting personalized treatment approaches across aesthetic surgeries. For instance, in January 2026, Johnson & Johnson MedTech launched the Arbrea Breast Simulator Surgeon App for MENTOR in the U.S. The tablet- and smartphone-based application generates a personalized 3D breast augmentation simulation in approximately 60 seconds, allowing surgeons and patients to visualize expected outcomes during consultation and facilitating informed surgical planning. In addition, in May 2026, Apyx Medical received expanded FDA 510(k) clearance for its AYON Body Contouring System, adding power-assisted liposuction functionality to the platform.

The invasive segment is expected to grow at a significant CAGR during the forecast period.

Age Group Insights

The 40-54 age group segment held a significant share of 46.5% in 2025. This age group represents the core consumer base for aesthetic medicine, driven by increasing demand for both preventive and corrective anti-aging treatments. Individuals aged 40-54 commonly seek procedures such as botulinum toxin injections, dermal fillers, laser skin resurfacing, body contouring, and facial rejuvenation to reduce visible signs of aging while maintaining a natural appearance. Higher disposable incomes, greater awareness of minimally invasive procedures, and growing acceptance of cosmetic enhancements further support the segment's dominance. In addition, the availability of advanced treatment options with shorter recovery times has encouraged repeat procedures and sustained demand among this demographic. In June 2025, Merz Aesthetics received U.S. FDA approval for XEOMIN (incobotulinumtoxinA) for the temporary improvement of moderate to severe platysma bands in adults. The approval expanded the use of XEOMIN for lower-face and neck rejuvenation procedures that are particularly popular among individuals aged 40-54, who increasingly seek minimally invasive treatments to address visible signs of aging while maintaining a natural appearance.

The 55-69 age group segment is expected to witness significant growth over the forecast period. Growth in this segment is primarily driven by the increasing preference for minimally invasive aesthetic procedures that address age-related concerns such as skin laxity, volume loss, deep wrinkles, and neck rejuvenation. Individuals in this age group generally have higher disposable incomes and are increasingly opting for non-surgical treatments that deliver natural-looking results with minimal downtime, helping them maintain a youthful appearance while avoiding invasive surgery.

End Use Insights

The clinics & aesthetic centers segment held a significant share of 47.7% in 2025. The growth is driven by the rapid expansion of medical spas, specialty aesthetic clinics, and multi-location aesthetic center networks across the U.S. Growing consumer demand for minimally invasive and personalized aesthetic treatments has encouraged providers to broaden their service portfolios by offering injectables, laser-based procedures, body contouring, skin rejuvenation, and regenerative aesthetic therapies under one roof. For instance, in January 2026, OrangeTwist announced a strategic alliance with SBC Medical Group Holdings and acquired six additional medical spa locations in Colorado and Nevada, expanding its network to 24 locations across six U.S. states. The expansion strengthened the company's national footprint and enhanced access to non-invasive aesthetic and wellness services through its growing med spa platform.

To learn more about this report, Download Free Sample Report

The medical spas segment is expected to witness the fastest growth in the U.S. aesthetic medicine services market over the forecast period. The growth is driven by increasing consumer preference for minimally invasive cosmetic procedures, rising disposable income, and growing awareness of preventive aesthetics. Medspa offers physician-supervised aesthetic treatments in a convenient outpatient setting, bridging the gap between traditional day spas and dermatology or plastic surgery clinics. These facilities provide a comprehensive range of non-surgical services, including botulinum toxin injections, dermal fillers, laser hair removal, skin resurfacing, chemical peels, microneedling, body contouring, tattoo removal, scar revision, and regenerative aesthetic treatments.

Metropolitan Cities Insights

New York accounted for the largest market share of 10.4% in 2025 and is expected to grow at the fastest CAGR during the forecast period. The growth is driven by its high concentration of board-certified plastic surgeons, dermatologists, and medical spas, coupled with a large, affluent population that demonstrates strong demand for both surgical and minimally invasive aesthetic procedures. New York also benefits from early adoption of advanced aesthetic technologies, a thriving medical tourism market, and growing consumer preference for facial rejuvenation, body contouring, and skin enhancement treatments. Continuous investments by leading aesthetic clinics and manufacturers further strengthen the state's market growth.

Key U.S. Aesthetic Medicine Company Insights

The market is fragmented, with the presence of many aesthetic medicine providers. The market players undertake several strategic initiatives, such as partnerships & collaborations, product launches, mergers & acquisitions, and geographical expansion to maintain their position and grow in the market.

Key U.S. Aesthetic Medicine Companies

• Ideal Image Inc.

• LaserAway

• Milan Laser Hair Removal

• SkinSpirit

• Sono Bello

• AirSculpt Technologies

• OrangeTwist

• Mia Aesthetics

• SEV Laser

• Chapter Aesthetic Studio

Recent Developments

• In April 2026, the U.S. FDA approved Merz Aesthetics’ Radiesse for treating décolletage wrinkles in adults 22 and older.

• In February 2026, Applied Medical Technology announced the U.S. launch of Explant Express, a breast implant suction retrieval device for the removal of ruptured implants.

 "The Explant Expressbreast implant suction retrieval device was designed to help plastic surgeons improve efficiency and control when removing ruptured breast implants."

-Joe Harr, Surgical Sales Manager

• In October 2025, Plexāā launched BLOOM⁴³ in the U.S. as a prehab and preconditioning platform for breast surgery patients. It combines a wearable home device with an app to improve skin resilience before surgery, thereby supporting wound healing and reducing complications after breast procedures.

• In May 2024, Olympus Cosmetic Group, backed by VSS Capital Partners, completed its acquisition of Artisan, a female-founded cosmetic surgery and medspa platform. The deal expands Olympus’s footprint in aesthetic services and strengthens its growth strategy by consolidating its surgery, dermatology, medspa, and non-surgical cosmetic offerings.

• In May 2024, the Aesthetic Society and The Aesthetic Foundation launched ARISE, a breast implant surveillance registry, to improve patient safety, outcomes tracking, and evidence-based care. The platform records implant and procedure data across augmentation, reconstruction, revision, and explant cases, creating a large database to support long-term monitoring and research.

"ARISE represents a leap forward in patient safety, outcomes research, and overall quality improvement in breast implant procedures. By leveraging the Aesthetic One app, ARISE collects unbiased, validated data that will be reported to regulatory bodies and utilized to collaborate with other international breast implant registries."

-Dr. Caroline Glicksman, President of The Aesthetic Foundation

U.S. Aesthetic Medicine Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 For this study, Grand View Research has segmented the U.S. aesthetic medicine market report based on procedure, age group, end use, and metropolitan cities:

• Procedure Outlook (Revenue, USD Billion, 2021 - 2033)

  • Invasive Procedures

    • Breast augmentation

    • Liposuction

    • Nose reshaping

    • Eyelid Surgery

    • Tummy tuck

    • Others

  • Non-invasive Procedures

    • Botox injections

    • Soft tissue fillers

    • Chemical peel

    • Laser hair removal

    • Microdermabrasion

    • Others

• Age Group Outlook (Revenue, USD Billion, 2021 - 2033)

  • 19 and under

  • 20-29

  • 30-39

  • 40-54

  • 55-69

  • 70+

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals

  • Clinics & Aesthetic Centers

  • Medspas

• Metropolitan Cities Outlook (Revenue, USD Billion, 2021 - 2033)

  • New York

  • Los Angeles

  • Chicago

  • Dallas

  • Houston

  • Washington

  • Miami

  • Philadelphia

  • Atlanta

  • Phoenix

  • Others

Research Methodology

The U.S. aesthetic medicine marketfigures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with eachU.S. aesthetic medicinesegment quantified using the revenue-capture definitions in the table below.

Estimation Model

1.1 Secondary Market Research

1.1.1 Data Sources

An extensive secondary research process was conducted to assess the U.S. aesthetic medicine market using information from:

Professional societies and industry associations: American Society of Plastic Surgeons (ASPS), International Society of Aesthetic Plastic Surgery (ISAPS), American Academy of Dermatology (AAD), American Society for Dermatologic Surgery (ASDS), and The MedSpa Association.

Government and regulatory agencies: U.S. Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), U.S. Census Bureau, and Bureau of Labor Statistics (BLS).

Company publications: Annual reports, SEC filings, investor presentations, earnings calls, press releases, and corporate websites.

Industry publications: Peer-reviewed journals, clinical studies, conference proceedings, and aesthetic medicine magazines.

Clinic audits: Public pricing, treatment offerings, memberships, and promotional packages from medical spas, dermatology clinics, and plastic surgery centers.

1.1.2 Analysis Focus

Secondary research focused on:

• Procedure-wise demand and utilization trends.

• Pricing across provider settings.

• Technology adoption and service portfolio expansion.

• Competitive landscape, mergers & acquisitions, and expansion activities.

• Regulatory framework governing aesthetic procedures and medical devices.

1.2 Primary Market Intelligence

Primary research was conducted to validate secondary findings and obtain current market insights regarding procedure volumes, pricing, technology adoption, and provider trends.

1.2.1 In-depth Interviews (IDIs)

Respondents

• Plastic surgeons

• Cosmetic dermatologists

• Aesthetic physicians

• Medical spa owners and managers

• Aesthetic clinic administrators

• Industry experts and consultants

• Device manufacturers and distributors

Discussion Areas

• Procedure mix and treatment volumes

• Pricing and promotional strategies

• Consumer preferences

• Technology adoption

• Capacity utilization

• Competitive landscape

• Market opportunities and challenges

1.2.2 Online Survey Program

The survey collected information on:

• Monthly procedure volumes

• Average realized pricing

• Invasive vs. non-invasive procedure mix

• Equipment utilization

• Repeat treatment rates

• Technology adoption

Patient acquisition and marketing trends

1.3 Market Size Estimation

The U.S. aesthetic medicine market was estimated using a bottom-up approach, where market revenue was calculated by multiplying the annual procedure volume by the realized average procedure price for each treatment category.

1.3.1 Step 1- Estimating Procedure Volumes

Procedure volumes were estimated using data from ASPS, ISAPS, industry associations, published literature, and company disclosures. These estimates were validated through primary interviews and surveys with plastic surgeons, dermatologists, aesthetic physicians, medical spas, and aesthetic clinics to capture procedure volumes across all major provider settings.

1.3.2 Step 2 - Estimating Average Procedure Price

Average procedure prices were derived from clinic pricing audits, medical spa websites, provider interviews, and survey responses. Realized prices reflected promotional discounts, bundled packages, memberships, and financing offers rather than advertised list prices.

1.3.3 Final Market Estimation

Revenue was calculated for each procedure by multiplying estimated procedure volumes by realized average prices. The results were aggregated across all procedure categories and end users, including hospitals, clinics & aesthetic centers, and medical spas. Final market estimates were validated through data triangulation using company revenues, clinic capacities, technology adoption, and expert insights.

Delivered Customizations

This report has been delivered with the following In-depth customizations